Clinical stage biopharmaceutical company, Artelo Biosciences, Inc., is dedicated to developing and bringing to market treatments that modulate the endocannabinoid system. Among its promising product candidates is ART27.13, a synthetic G protein-coupled receptor agonist that is currently in Phase 1b/2a clinical trials for treating cancer-related anorexia. Other exciting products in Artelo's pipeline include ART12.11, a synthetic cannabidiol cocrystal for treating inflammatory bowel disease and post-traumatic stress disorder (PTSD), and ART26.12, a fatty acid binding protein 5 inhibitor that holds potential for treating prostate and breast cancer and PTSD. Artelo Biosciences, Inc. is also collaborating with Trinity College Dublin to research potential treatments for cancer cachexia using ART27.13. Founded in 2011 and previously known as Reactive Medical, Inc., the California-based company changed its name to Artelo Biosciences, Inc. in April 2017.
Artelo Biosciences's ticker is ARTL
The company's shares trade on the NASDAQ stock exchange
They are based in La Jolla, California
There are 1-10 employees working at Artelo Biosciences
It is artelobio.com
Artelo Biosciences is in the Healthcare sector
Artelo Biosciences is in the Biotechnology industry
The following five companies are Artelo Biosciences's industry peers: